A landscape of driver mutations in melanoma

Cited by (1,006)

Items 201–300 of 1,006

1. Computational approaches to identify functional genetic variants in cancer genomes
   Abel González-Pérez, Núria López-Bigas, Ville Mustonen, Graham R. S. Ritchie, Adam P. Butler, Serge Dronov, Boris A. Reva, Chris Sander, Paul Flicek, Pau Creixell et al. · 2013 · Nature Methods
2. Melanoma: Molecular Pathogenesis and Therapeutic Management.
   Yuxin Liu, M. Saeed Sheikh · 2014 · PubMed
3. The genomic landscape of cutaneous melanoma
   Tongwu Zhang, Ken Dutton‐Regester, Kevin M. Brown, Nicholas K. Hayward · 2016 · Pigment Cell & Melanoma Research
4. The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
   Ian R. Watson, Li Li, Peter K. Cabeceiras, Mozhdeh Mahdavi, Tony Gutschner, Giannicola Genovese, Guocan Wang, Zhuangna Fang, James M. Tepper, Katherine Stemke‐Hale et al. · 2014 · Cancer Research
5. An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer
   Ophélia Maertens, Karen M. Cichowski · 2014 · Advances in Biological Regulation
6. Activating MET kinase rearrangements in melanoma and Spitz tumours
   Iwei Yeh, Thomas Botton, Eric Talevich, Alan Hunter Shain, Alyssa J. Sparatta, Arnaud de la Fouchardière, Thaddeus W. Mully, Jeffrey P. North, María C. Garrido, Alexander Gagnon et al. · 2015 · Nature Communications
7. Rho signaling research: history, current status and future directions
   Shuh Narumiya, Dean Thumkeo · 2018 · FEBS Letters
8. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma
   Jared J. Gartner, Stephen C.J. Parker, Todd D. Prickett, Ken Dutton‐Regester, Michael L. Stitzel, Jimmy Lin, Sean R. Davis, Vijaya Lakshmi Simhadri, Sujata S. Jha, Nobuko Katagiri et al. · 2013 · Proceedings of the National Academy of Sciences
9. Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms
   Hadir Marei, Angeliki Malliri · 2016 · Small GTPases
10. A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening
    Jouhyun Jeon, Satra Nim, Joan Teyra, Alessandro Datti, Jeffrey L. Wrana, Sachdev S. Sidhu, Jason Moffat, Philip M. Kim · 2014 · Genome Medicine
11. VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
    Xiaosai Yao, Jing Ying Tan, Kevin Junliang Lim, Joanna Koh, Wen Fong Ooi, Zhimei Li, Dachuan Huang, Manjie Xing, Yang Sun Chan, James Zhengzhong Qu et al. · 2017 · Cancer Discovery
12. Why is melanoma so metastatic?
    Russell R. Braeuer, Ian R. Watson, Chang‐Jiun Wu, Aaron K. Mobley, Takafumi Kamiya, Einav Shoshan, Menashe Bar‐Eli · 2013 · Pigment Cell & Melanoma Research
13. Rho GTPases in cancer: friend or foe?
    Julius Svensmark, Cord Brakebusch · 2019 · Oncogene
14. Melanoma metastasis: new concepts and evolving paradigms
    William Damsky, Nicholas Theodosakis, Marcus Bosenberg · 2013 · Oncogene
15. Protein oxidation, UVA and human DNA repair
    Peter Karran, Reto Brem · 2016 · DNA repair
16. NRAS-mutant melanoma: current challenges and future prospect
    Eva Muñoz‐Couselo, Esther Zamora, Carolina Ortiz, Jesús Soberino-García, José Manuel Pérez-García · 2017 · OncoTargets and Therapy
17. Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
    Naghavian, Reza, Faigle, Wolfgang, Oldrati, Pietro, Wang, Jian, Toussaint, Nora C., Qiu, Yuhan, Medici, Gioele, Wacker, Marcel, Freudenmann, Lena K., Bonté, Pierre-Emmanuel et al. · 2023 · Nature
18. The consequences for human health of stratospheric ozone depletion in association with other environmental factors
    Lucas, R. M., Norval, M., Neale, R. E., Young, A. R., de Gruijl, F. R., Takizawa, Y., van der Leun, J. C. · 2014 · Photochemical & Photobiological Sciences
19. The cancer COMPASS: navigating the functions of MLL complexes in cancer
    David J. Ford, Andrew K. Dingwall · 2015 · Cancer Genetics
20. A step-by-step microRNA guide to cancer development and metastasis
    Georgios S. Markopoulos, Eugenia Roupakia, Maria Tokamani, Evangelia Chavdoula, Maria Hatziapostolou, Christos Polytarchou, Kenneth B. Marcu, Athanasios G. Papavassiliou, Raphael Sandaltzopoulos, Evangelos Kolettas · 2017 · Cellular Oncology
21. MITF and UV responses in skin: From pigmentation to addiction
    Nathalie T. Nguyen, David E. Fisher · 2018 · Pigment Cell & Melanoma Research
22. Dabrafenib and its potential for the treatment of metastatic melanoma
    Rajmohan Murali, Alexander Maxwell Menzies, Georgina Venetia Long · 2012 · Drug Design Development and Therapy
23. MUFFINN: cancer gene discovery via network analysis of somatic mutation data
    Ara Cho, Jung Eun Shim, Eiru Kim, Fran Supek, Ben Lehner, Insuk Lee · 2016 · Genome biology
24. Somatic driver mutations in melanoma
    Bobby Y. Reddy, David Michael Miller, Hensin Tsao · 2017 · Cancer
25. Interactome INSIDER: a structural interactome browser for genomic studies
    Michael J. Meyer, Juan Felipe Beltrán, Siqi Liang, Robert Fragoza, Aaron Rumack, Jin Hua Liang, Xiaomu Wei, Haiyuan Yu · 2018 · Nature Methods
26. MiT/TFE Family of Transcription Factors, Lysosomes, and Cancer
    Rushika M. Perera, Chiara Di Malta, Andrea Ballabio · 2018 · Annual Review of Cancer Biology
27. Reduced mutation rate in exons due to differential mismatch repair
    Joan Frigola, Radhakrishnan Sabarinathan, Loris Mularoni, Ferran Muiños, Abel González-Pérez, Núria López-Bigas · 2017 · Nature Genetics
28. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
    Clemens Krepler, Katrin Sproesser, Patricia A. Brafford, Marilda Beqiri, Bradley Garman, Min Xiao, Batool Shannan, Andrea K. Watters, Michela Perego, Gao Zhang et al. · 2017 · Cell Reports
29. Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival
    Gaurav Pathria, David A. Scott, Yongmei Feng, Joo Sang Lee, Yu Fujita, Gao Zhang, Avinash D Sahu, Eytan Ruppin, Meenhard Herlyn, Andrei L. Osterman et al. · 2018 · The EMBO Journal
30. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
    Julia Reinhardt, Jennifer Landsberg, Jonathan Leo Schmid-Burgk, Bartomeu Bibiloni Ramis, Tobias Bald, Nicole Glodde, Dorys Lopez-Ramos, Arabella Young, Shin Foong Ngiow, Daniel Nettersheim et al. · 2017 · Cancer Research
31. NTRK3 kinase fusions in Spitz tumours
    Iwei Yeh, Meng Kian Tee, Thomas Botton, Alan Hunter Shain, Alyssa J. Sparatta, Alexander Gagnon, Swapna S. Vemula, María C. Garrido, Kenji Nakamaru, Takeshi Isoyama et al. · 2016 · The Journal of Pathology
32. NRAS mutant melanoma: Towards better therapies
    Tijana Randic, Ines Kozar, Christiane Margue, Jochen Sven Utikal, Stephanie Kreis · 2021 · Cancer Treatment Reviews
33. RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action
    Julien Masliah‐Planchon, Simon Garinet, Éric Pasmant · 2015 · Oncotarget
34. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
    Marcel A. Deken, Jules Gadiot, Ekaterina S. Jordanova, Ruben Lacroix, Melissa M. J. van Gool, Paula Kroon, Cristina Pineda, Marnix H. Geukes Foppen, Richard A. Scolyer, Ji‐Ying Song et al. · 2016 · OncoImmunology
35. Beyond BRAFV600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma
    Alan E. Siroy, Genevieve Marie Boland, Denái R. Milton, Jason Roszik, Silva Frankian, Jared C. Malke, Lauren Elaine Haydu, Victor Gerardo Prieto, Michael T. Tetzlaff, Doina S. Ivan et al. · 2014 · Journal of Investigative Dermatology
36. Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression
    Yong‐Chen Lu, Xin Yao, Yong F. Li, Mona El‐Gamil, Mark E. Dudley, James Chih-Hsin Yang, Jorge R. Almeida, Daniel C. Douek, Yardena Samuels, Steven A. Rosenberg et al. · 2013 · The Journal of Immunology
37. Applications and analysis of targeted genomic sequencing in cancer studies
    Findlay Bewicke‐Copley, Emil Arjun Kumar, Giuseppe Palladino, Koorosh Korfi, Jun Wang · 2019 · Computational and Structural Biotechnology Journal
38. Small GTPases
    David J. Reiner · 2016 · WormBook
39. Detection of Exosomal miRNAs in the Plasma of Melanoma Patients
    Susan R. Pfeffer, Kenneth F. Grossmann, Pamela B. Cassidy, Chuan He Yang, Meiyun Fan, Levy Kopelovich, Sancy Ann Leachman, Lawrence M. Pfeffer · 2015 · Journal of Clinical Medicine
40. Roles of UVA radiation and DNA damage responses in melanoma pathogenesis
    Khan, Aiman Q., Travers, Jeffrey B., Kemp, Michael G. · 2018 · Environmental and Molecular Mutagenesis
41. UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer
    Liu-Smith, Feng, Jia, Jinjing, Zheng, Yan · 2017 · Advances in Experimental Medicine and Biology
42. An Alternative Approach to ChIP-Seq Normalization Enables Detection of Genome-Wide Changes in Histone H3 Lysine 27 Trimethylation upon EZH2 Inhibition
    Brian S. Egan, Chih-Chi Yuan, Madeleine Craske, Paul Labhart, Gulfem Dilek Guler, David P. Arnott, Tobias M Maile, Jennifer Busby, Chisato Henry, Theresa Kathleen Kelly et al. · 2016 · PLoS ONE
43. MERTK receptor tyrosine kinase is a therapeutic target in melanoma
    Jennifer Schlegel, Maria J. Sambade, Susan Sather, Stergios J. Moschos, Aik Choon Tan, Amanda Winges, Deborah DeRyckere, Craig C. Carson, Dimitri G. Trembath, John J. Tentler et al. · 2013 · Journal of Clinical Investigation
44. Melanoma Epidemiology and Prevention
    Marianne Berwick, David B. Buller, Anne Elizabeth Cust, Richard P. Gallagher, Tim K. Lee, Frank Louis Meyskens, Shaily Pandey, Nancy E. Thomas, Marit Bragelien Veierød, Sarah V. Ward · 2015 · Cancer treatment and research
45. Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance
    Farzana Ahmed, Nikolas K. Haass · 2018 · Frontiers in Oncology
46. Gender Disparity and Mutation Burden in Metastatic Melanoma
    Sameer Gupta, Mykyta Artomov, William Bernard Goggins, Mark J. Daly, Hensin Tsao · 2015 · JNCI Journal of the National Cancer Institute
47. EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation
    William D. Bradley, Shilpi Arora, Jennifer Busby, Srividya Balasubramanian, Victor S. Gehling, Christopher G. Nasveschuk, Rishi G. Vaswani, Chih-Chi Yuan, Charlie Hatton, Feng Zhao et al. · 2014 · Chemistry & Biology
48. Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties
    Yijun Gao, Matthew T. Chang, Daniel McKay, Na Na, Bing Zhou, Rona D. Yaeger, Neilawattie M. Torres, Keven Muniz, Matthias Drosten, Mariano Barbacid et al. · 2018 · Cancer Discovery
49. PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?
    Chiara Bazzichetto, Fabiana Conciatori, Matteo Pallocca, Italia Falcone, Maurizio Fanciulli, Francesco Cognetti, Michèle Milella, Ludovica Ciuffreda · 2019 · Cancers
50. Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi
    Iwei Yeh, Ursula E. Lang, Emeline Durieux, Meng Kian Tee, Aparna Jorapur, Alan Hunter Shain, Véronique Haddad, Daniel Pissaloux, Xu Chen, Lorenzo Cerroni et al. · 2017 · Nature Communications
51. MAP2K1 ( MEK1 ) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking
    Maria E. Arcila, Alexander Edward Dela Cruz Drilon, Brooke E. Sylvester, Christine Marie Lovly, Laetitia A Borsu, Boris A. Reva, Mark G. Kris, David B. Solit, Marc Ladanyi · 2014 · Clinical Cancer Research
52. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
    Max S. Schreuer, Geert Meersseman, Sari Van Den Herrewegen, Yanina Jeanne Leona Jansen, Inès Chevolet, Ambre Bott, Sofie Wilgenhof, Teofila Seremet, Bart Jacobs, Ronald Buyl et al. · 2016 · Journal of Translational Medicine
53. Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma
    Julien Ablain, Mengshu Xu, Harriet Rothschild, Richard C. Jordan, Jeffrey K. Mito, Brianne H. Daniels, Caitlin Bell, Nancy M. Joseph, Hong Gyun Wu, Boris C. Bastian et al. · 2018 · Science
54. Fibroblast-mediated drug resistance in cancer
    Kim H.T. Paraiso, Keiran S.M. Smalley · 2013 · Biochemical Pharmacology
55. The mutational burden of acral melanoma revealed by whole‐genome sequencing and comparative analysis
    Simon J. Furney, Samra Turajlic, Gordon Stamp, Janet Thomas, Andrew J Hayes, D. Strauß, Mike Gavrielides, Wei Xing, Martin Eric Gore, James Larkin et al. · 2014 · Pigment Cell & Melanoma Research
56. Oxidative stress in thyroid carcinomas: biological and clinical significance
    Rabii Ameziane El Hassani, Camille Buffet, Sophie Leboulleux, Corinne Dupuy · 2019 · Endocrine Related Cancer
57. The genomic landscapes of individual melanocytes from human skin
    Jessica Tang, Eleanor Fewings, Darwin Chang, Hanlin Zeng, Shanshan Liu, Aparna Jorapur, R.L. Belote, Andrew S. McNeal, Tuyet M. Tan, Iwei Yeh et al. · 2020 · Nature
58. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
    Nikolaj Pagh Kristensen, Christina Heeke, Siri A. Tvingsholm, Annie Borch, Arianna Draghi, Michael Douglas Crowther, Ibel Carri, Kamilla Kjærgaard Munk, Jeppe Sejerø Holm, Anne-Mette Bjerregaard et al. · 2021 · Journal of Clinical Investigation
59. Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma
    Winnie S. Liang, William P.D. Hendricks, Jeffrey Kiefer, Jessica E. Schmidt, Shobana Sekar, John David Carpten, David Wesley Craig, Jonathan R. Adkins, Lori Cuyugan, Zarko Manojlovic et al. · 2017 · Genome Research
60. Treatment of NRAS-mutant melanoma
    Johnson, Douglas B., Puzanov, Igor · 2015 · Current Treatment Options in Oncology
61. Engaging chromatin: PRC2 structure meets function
    Paul Chammas, Ivano Mocavini, Luciano Di Croce · 2019 · British Journal of Cancer
62. The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition
    Teresa Maria Santos Amaral, Tobias W. Sinnberg, Friedegund Elke Meier, Clemens Krepler, Mitchell Paul Levesque, Heike Niessner, Claus Garbe · 2017 · European Journal of Cancer
63. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation
    Yadav, Vipin, Burke, Teresa F., Huber, Lysiane, Van Horn, Robert D., Zhang, Youyan, Buchanan, Sean G., Chan, Edward M., Starling, James J., Beckmann, Richard P., Peng, Sheng-Bin · 2014 · Molecular Cancer Therapeutics
64. Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses
    Leandro Machado Colli, Mitchell J. Machiela, Timothy A. Myers, Lea Jessop, Kai F. Yu, Stephen Jacob Chanock · 2016 · Cancer Research
65. NF 1‐mutated melanoma tumors harbor distinct clinical and biological characteristics
    Helena Cirenajwis, Martin Lauss, Henrik Ekedahl, Therese Törngren, Anders Kvist, Lao H. Saal, Hakan Lars Olsson, Johan Staaf, Ana Carneiro, Christian Ingvar et al. · 2017 · Molecular Oncology
66. BRAF — a tumour-agnostic drug target with lineage-specific dependencies
    Hanrahan, Aphrothiti J., Chen, Ziyu, Rosen, Neal, Solit, David B. · 2024 · Nature Reviews Clinical Oncology
67. Evolution of delayed resistance to immunotherapy in a melanoma responder
    David Liu, Jia‐Ren Lin, Emily J. Robitschek, Gyulnara G. Kasumova, Alex Heyde, Alvin Shi, Adam Kraya, Gao Zhang, Tabea O. C. Moll, Dennie Tompers Frederick et al. · 2021 · Nature Medicine
68. Approaches of targeting Rho GTPases in cancer drug discovery
    Yuan Lin, Yi Zheng · 2015 · Expert Opinion on Drug Discovery
69. Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
    Federica Catalanotti, David B. Solit, Melissa P. Pulitzer, Michael F. Berger, Sasinya N. Scott, Tunc A. Iyriboz, Mario E. Lacouture, Katherine S. Panageas, Jedd D. Wolchok, Richard D. Carvajal et al. · 2013 · Clinical Cancer Research
70. Excessive Polyamine Generation in Keratinocytes Promotes Self-RNA Sensing by Dendritic Cells in Psoriasis
    Fangzhou Lou, Yang Sun, Zhenyao Xu, Liman Niu, Zhikai Wang, Siyu Deng, Zhaoyuan Liu, Hong Zhou, Jing Bai, Qianqian Yin et al. · 2020 · Immunity
71. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma
    Irfan Ahmed Asangani, Paul W. Harms, Lois M. Dodson, Mithil B. Pandhi, Lakshmi Priya Kunju, Christopher A. Maher, Douglas Randall Fullen, Timothy M. Johnson, Thomas J. Giordano, Nallasivam Palanisamy et al. · 2012 · Oncotarget
72. Structural basis for endosomal trafficking of diverse transmembrane cargos by PX-FERM proteins
    Ghai, Rajesh, Bugarcic, Andrea, Liu, Huadong, Norwood, Suzanne J., Skeldal, Sune, Coulson, Elizabeth J., Li, Shawn Shun-Cheng, Teasdale, Rohan D., Collins, Brett M. · 2013 · Proceedings of the National Academy of Sciences
73. Molecular drivers of cellular metabolic reprogramming in melanoma
    Cecilie Abildgaard, Per Guldberg · 2015 · Trends in Molecular Medicine
74. Melanoma: From Melanocyte to Genetic Alterations and Clinical Options
    Corine Bertolotto · 2013 · Scientifica
75. BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage
    Victoria Mar, Stephen Q. Wong, Jason Li, Richard A. Scolyer, Catriona McLean, Anthony T. Papenfuss, Richard W. Tothill, Hojabr Kakavand, Graham J. Mann, John F. Thompson et al. · 2013 · Clinical Cancer Research
76. Targeting RAS-mutant cancers: is ERK the key?
    Meagan B. Ryan, C. Der, A. Wang-Gillam, A. Cox · 2015 · Trends in Cancer
77. Oxidatively-generated damage to DNA and proteins mediated by photosensitized UVA
    Reto Brem, Melisa Guven, Peter Karran · 2016 · Free Radical Biology and Medicine
78. Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin
    Chul‐Hwan Lee, Jia-Ray Yu, Sunil Kumar, Ying Jin, Gary LeRoy, Natarajan V. Bhanu, Syuzo Kaneko, Benjamin A. Garcia, Andrew D. Hamilton, Danny Reinberg · 2018 · Molecular Cell
79. Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene
    Bárbara Fontanals-Cirera, Dan Hasson, Chiara Vardabasso, Raffaella Di Micco, Praveen Kumar Agrawal, Asif H. Chowdhury, Madeleine Gantz, Ana de Pablos-Aragoneses, Ari Morgenstern, Pamela Wu et al. · 2017 · Molecular Cell
80. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
    Teresa L. Helsten, Maria Clemence Schwaederle, Razelle Kurzrock · 2015 · Cancer and Metastasis Reviews
81. Transforming mutations of RAC guanosine triphosphatases in human cancers
    Masahito Kawazu, Toshihide Ueno, Kenji Kontani, Yoshitaka Ogita, Mizuo Ando, Kazutaka Fukumura, Azusa Yamato, Manabu Soda, Kengo Takeuchi, Yoshio Miki et al. · 2013 · Proceedings of the National Academy of Sciences
82. Histopathologic classification and prognostic factors of melanoma: a 2021 update
    Mattheos Bobos · 2021 · Italian Journal of Dermatology and Venereology
83. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer
    Johnson, Gary L., Stuhlmiller, Timothy J., Angus, Steven P., Zawistowski, Jon S., Graves, Lee M. · 2014 · Clinical Cancer Research
84. Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression
    Elisabetta Panza, Paola De Cicco, Chiara Armogida, Giosuè Scognamiglio, Vincenzo Gigantino, Gerardo Botti, Domenico Germano, Maria Napolitano, Andreas Papapetropoulos, Mariarosaria Bucci et al. · 2014 · Pigment Cell & Melanoma Research
85. Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
    Emanuela Romano, Sylvain Pradervand, Alexandra Paillusson, Johann Weber, Keith Harshman, Katja Muehlethaler, Daniel E. Speiser, Solange Peters, Donata Rimoldi, Olivier Alain Michielin · 2013 · Clinical Cancer Research
86. The landscape of driver mutations in cutaneous squamous cell carcinoma
    Darwin Chang, Alan Hunter Shain · 2021 · npj Genomic Medicine
87. Inflammation lights the way to metastasis
    Seth B. Coffelt, Karin E. de Visser · 2014 · Nature
88. Insertions and Deletions Target Lineage-Defining Genes in Human Cancers
    Marcin B. Imielinski, Guangwu Guo, Matthew M. Meyerson · 2017 · Cell
89. Epigenetics of malignant melanoma
    Bruce Moran, Romina Silva, Antoinette Sabrina Perry, William M. Gallagher · 2017 · Seminars in Cancer Biology
90. Are there multiple cells of origin of Merkel cell carcinoma?
    Joel Chaim Sunshine, Nadine S. Jahchan, Julien Sage, Jaehyuk Choi · 2018 · Oncogene
91. Germline MC1R status influences somatic mutation burden in melanoma
    Robles-Espinoza, Carla Daniela, Roberts, Nicola D., Chen, Shuyang, Leacy, Finbarr P., Alexandrov, Ludmil B., Pornputtapong, Natapol, Halaban, Ruth, Krauthammer, Michael, Cui, Rutao, Timothy Bishop, D. et al. · 2016 · Nature Communications
92. RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance
    Daniël A. Lionarons, David C. Hancock, Sareena Rana, Philip East, Christopher Moore, Miguel Manuel Murillo, Joana Carvalho, Bradley Spencer‐Dene, Eleanor Herbert, Gordon Stamp et al. · 2019 · Cancer Cell
93. NF1 Mutations Are Common in Desmoplastic Melanoma
    Thomas Wiesner, Maija H. Kiuru, Sasinya N. Scott, Maria E. Arcila, Allan C. Halpern, Travis J. Hollmann, Michael F. Berger, Klaus Johannes BUSAM · 2015 · The American Journal of Surgical Pathology
94. Understanding mutagenesis through delineation of mutational signatures in human cancer
    Petljak, Mia, Alexandrov, Ludmil B. · 2016 · Carcinogenesis
95. mutation3D: Cancer Gene Prediction Through Atomic Clustering of Coding Variants in the Structural Proteome
    Michael J. Meyer, Ryan Lapcevic, Alfonso E. Romero, Mark Yoon, Jishnu Das, Juan Felipe Beltrán, Matthew E. Mort, Peter D. Stenson, D.N. Cooper, Alberto Paccanaro et al. · 2016 · Human Mutation
96. Variation Interpretation Predictors: Principles, Types, Performance, and Choice
    Abhishek Niroula, Mauno Vihinen · 2016 · Human Mutation
97. Genomic profiling reveals mutational landscape in parathyroid carcinomas
    Chetanya Pandya, Andrew V. Uzilov, Justin Bellizzi, Chun Yee Lau, Aye S. Moe, Maya Strahl, Wissam Hamou, Leah C. Newman, Marc Y. Fink, Yevgeniy Antipin et al. · 2017 · JCI Insight
98. Exome sequencing reveals frequent inactivating mutations inARID1A, ARID1B, ARID2andARID4Ain microsatellite unstable colorectal cancer
    Tatiana Cajuso, Ulrika A. Hänninen, Johanna Kondelin, Alexandra E. Gylfe, Tomas J. Tanskanen, Riku Katainen, Esa Pitkänen, Heikki Ristolainen, Eevi Kaasinen, Minna Taipale et al. · 2014 · International Journal of Cancer
99. The mutational landscape of chromatin regulatory factors across 4,623 tumor samples
    Abel González-Pérez, Alba Jené-Sanz, Núria López-Bigas · 2013 · Genome biology
100. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
     Sibylle Cocciardi, Anna Dolnik, Silke Kapp‐Schwoerer, Frank G. Rücker, Susanne Lux, Tamara J. Blätte, Sabrina Skambraks, Jan Krönke, Florian Heinrich Heidel, Tina M. Schnoeder et al. · 2019 · Nature Communications